Longeveron Inc. (LGVN) is a publicly traded company in the Healthcare sector, operating within the Biotechnology industry. The company is headquartered in Miami, FL, United States. The current CEO is Stephen H. Willard.
LGVN has IPO date of 2021-02-12, 25 full-time employees, listed on the NASDAQ Capital Marke, a market capitalization of $26.1M.
Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions. The company's lead investigational product is the LOMECEL-B, a cell-based therapy product that is derived from culture-expanded medicinal signaling cells that are sourced from bone marrow of young healthy adult donors. It is conducting Phase 1 and 2 clinical trials in various indications, such as aging frailty, alzheimer's disease, metabolic syndrome, acute respiratory distress syndrome, and hypoplastic left heart syndrome. The company was incorporated in 2014 and is based in Miami, Florida.
